Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
NCT05789589Phase 2Suspended
- Sponsor
- Baptist Health South Florida
- Start
- Nov 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azeliragon in brain metastases, sponsored by Baptist Health South Florida. Primary endpoint: Total Dose-Limiting Toxicities at 4 weeks. Started Nov 2023; status: suspended.
02
Drugs
azeliragon
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT05789589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789589.